Ipsen: cross-border access for the specialty portfolio

Quick orientation

Ipsen S.A. is a French biopharmaceutical company headquartered in Boulogne-Billancourt with US operations in Cambridge, Massachusetts. The 2023 acquisition of Albireo Pharma added the pediatric cholestatic liver disease franchise. Ipsen's specialty footprint is anchored in oncology (Cabometyx co-marketed with Exelixis; Onivyde for advanced pancreatic cancer; Somatuline Depot in neuroendocrine tumors and acromegaly; Decapeptyl in prostate cancer), rare pediatric hepatology (Bylvay for PFIC and biliary atresia), rare disease (Sohonos for fibrodysplasia ossificans progressiva), and the adult primary biliary cholangitis indication (Iqirvo).

Portfolio in cross-border NPP scope

Bylvay (odevixibat)

Apical sodium-dependent bile acid transporter (IBAT) inhibitor approved for pruritus in PFIC age 3 months and older, and for biliary atresia age 1 month and older. International requests come from PFIC and BA pediatric patients in MENA and India where consanguinity-driven cholestatic liver disease prevalence is meaningful and where no other on-label disease-modifying therapy is locally registered.

Iqirvo (elafibranor)

PPAR-alpha and PPAR-delta agonist approved for primary biliary cholangitis in adults with inadequate response to or intolerance of UDCA. International requests come from PBC patients in MENA and India who have failed UDCA monotherapy and where the locally registered options remain limited to obeticholic acid.

Sohonos (palovarotene)

Retinoic acid receptor gamma agonist approved for fibrodysplasia ossificans progressiva (FOP) in patients age 8 and older for females and 10 and older for males. International requests come from FOP patients in MENA and India where this ultra-rare disease has no other on-label disease-modifying option.

Cabometyx (cabozantinib, co-marketed with Exelixis)

Tyrosine kinase inhibitor approved for renal cell carcinoma (first-line and after VEGF therapy), hepatocellular carcinoma after sorafenib, differentiated thyroid cancer, and newer neuroendocrine tumor indications. International requests come from RCC, HCC, and DTC patients in MENA and India where the locally registered TKI panel excludes Cabometyx.

Onivyde (irinotecan liposome)

Liposomal irinotecan approved for metastatic adenocarcinoma of the pancreas (post-gemcitabine, with leucovorin and fluorouracil) and for first-line metastatic pancreatic adenocarcinoma with NALIRIFOX. International requests come from pancreatic cancer patients in MENA and India where second-line on-label options are limited.

Somatuline Depot (lanreotide)

Somatostatin analog long-acting injection approved for gastroenteropancreatic neuroendocrine tumors and for acromegaly. International requests come from GEP-NET patients in MENA and India where local somatostatin analog supply is intermittent.

Decapeptyl (triptorelin)

GnRH agonist approved for advanced prostate cancer and used in pediatric central precocious puberty. International requests come from prostate cancer patients where the specific 11.25mg three-month or 22.5mg six-month depot is locally unavailable.

Dysport (abobotulinumtoxinA)

Type A botulinum toxin approved for cervical dystonia, glabellar lines, upper and lower limb spasticity in adults and pediatric patients. International requests come from spasticity patients in MENA and India where the specific dosing or pediatric indication is not locally registered.

Why patients route Ipsen products through cross-border NPP

Three patterns dominate. First, the Albireo-origin pediatric cholestatic franchise (Bylvay) serves PFIC and biliary atresia populations that are meaningfully larger in MENA than in Western populations due to consanguinity. Second, Iqirvo and the PBC second-line population is too new globally for most non-US labels. Third, Sohonos and the FOP population is ultra-rare and structurally cross-border by default. The Ipsen CARES patient assistance program is restricted to US residents.

Manufacturer engagement posture

Reserve Meds coordinates Ipsen-manufactured US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized Ipsen distributor. All Reserve Meds orders are cash-pay at firm-quote pricing.

For Ipsen market access teams: Reserve Meds maintains structured demand visibility across pediatric hepatology, oncology, neuroendocrine, and ultra-rare franchises. If your group is sizing pre-registration demand in MENA and India, we are open to a structured conversation under NDA.

Common cross-border destinations for the Ipsen portfolio

The pediatric cholestatic franchise (Bylvay) concentrates in pediatric hepatology centers in Saudi Arabia, India, Egypt, and the UAE. The PBC franchise (Iqirvo) tracks adult hepatology centers across the Gulf and India. The neuroendocrine and oncology franchises (Cabometyx, Onivyde, Somatuline) serve oncology specialist centers. Sohonos and ultra-rare disease serves tertiary referral.

What Reserve Meds provides

For every Ipsen product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a Ipsen product and want a firm quote can start a request below.

Start a request for a Ipsen product

Next step for Ipsen teams

If you are on the Ipsen access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.